Today we begin our live coverage of BIO 2009. We've already met with a number of attendees and companies promoting themselves at the show. Despite concerns about the economy, attendence is strong, and the line to get into the Elton John keynote started forming an hour before the speech started. We'll have details on his HIV/AIDS speech tomorrow, but in the meantime, here are our observations from day one of the show.
Panel examines 'rifle-shot' approach to drug development
by Maureen Martino
This morning I attended Ernst & Young's Global Biotechnology Report session, which examined what led the industry to the state it's in now and how to survive the financial crisis. The speakers seemed particularly concerned about the lean, mean approach some biotechs have adopted over the last year, and the implications it has for long-term drug innovation. Report
Mass. attempts R&D/manufacturing balance
by George Miller
Call me a native son, but as someone from Massachusetts whose work involves the biotech industry I had to sit in on the panel session given by the state's delegation. I wanted to see how the Massachusetts pitch to biotech manufacturers compared with those I'd heard recently from other states and regions in the country. Report